JP2007502777A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502777A5 JP2007502777A5 JP2006523414A JP2006523414A JP2007502777A5 JP 2007502777 A5 JP2007502777 A5 JP 2007502777A5 JP 2006523414 A JP2006523414 A JP 2006523414A JP 2006523414 A JP2006523414 A JP 2006523414A JP 2007502777 A5 JP2007502777 A5 JP 2007502777A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- alkoxycarbonyl
- cycloalkoxy
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 26
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 24
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 24
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 24
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 24
- 125000004104 aryloxy group Chemical group 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 24
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 24
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 24
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 22
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 22
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- -1 Ali Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229910052697 platinum Inorganic materials 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 241000700647 Variola virus Species 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 241000829111 Human polyomavirus 1 Species 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 241001505332 Polyomavirus sp. Species 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 150000003057 platinum Chemical class 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 208000022453 Clostridium infectious disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000031998 Mycobacterium Infections Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010062212 Neisseria infection Diseases 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010048249 Yersinia infections Diseases 0.000 description 1
- 208000025079 Yersinia infectious disease Diseases 0.000 description 1
- DOLOANSKJAJTSN-UHFFFAOYSA-N [O-][N+]([Pt+3])=O Chemical compound [O-][N+]([Pt+3])=O DOLOANSKJAJTSN-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000004776 molecular orbital Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48122603P | 2003-08-13 | 2003-08-13 | |
| US51558003P | 2003-10-30 | 2003-10-30 | |
| US51994303P | 2003-11-14 | 2003-11-14 | |
| US52529503P | 2003-11-25 | 2003-11-25 | |
| PCT/US2004/026393 WO2005016946A2 (en) | 2003-08-13 | 2004-08-13 | Platinum complexes for the treatment of tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502777A JP2007502777A (ja) | 2007-02-15 |
| JP2007502777A5 true JP2007502777A5 (enExample) | 2007-09-27 |
Family
ID=34199238
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523414A Pending JP2007502777A (ja) | 2003-08-13 | 2004-08-13 | 腫瘍の処置のための白金錯体 |
| JP2006523413A Pending JP2007502301A (ja) | 2003-08-13 | 2004-08-13 | 腫瘍細胞の増殖を阻害するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523413A Pending JP2007502301A (ja) | 2003-08-13 | 2004-08-13 | 腫瘍細胞の増殖を阻害するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US7238372B2 (enExample) |
| EP (2) | EP1664070B1 (enExample) |
| JP (2) | JP2007502777A (enExample) |
| AT (2) | ATE453653T1 (enExample) |
| AU (3) | AU2004264421B2 (enExample) |
| CA (2) | CA2535584A1 (enExample) |
| DE (2) | DE602004015811D1 (enExample) |
| WO (2) | WO2005023824A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023824A2 (en) | 2003-08-13 | 2005-03-17 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| US20050288365A1 (en) | 2004-01-06 | 2005-12-29 | Heidi Kay | Platinum complexes and methods for inhibiting tumor cell proliferation |
| CA2563305A1 (en) * | 2004-04-09 | 2005-11-24 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
| CA2587779A1 (en) | 2004-11-10 | 2007-01-18 | University Of South Florida | Platinum complexes for targeted drug delivery |
| WO2006065894A2 (en) | 2004-12-14 | 2006-06-22 | University Of South Florida | Methods for inhibiting stat3 signaling in immune cells |
| DE102004060934A1 (de) * | 2004-12-17 | 2006-06-29 | Wacker Chemie Ag | Vernetzbare Polyorganosiloxanmassen |
| AU2006266446B2 (en) * | 2005-06-30 | 2011-03-10 | Bionumerik Pharmaceuticals, Inc. | Monoazole ligand platinum analogs |
| WO2007006019A1 (en) * | 2005-07-06 | 2007-01-11 | University Of South Florida | Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression |
| US8133692B2 (en) * | 2005-07-20 | 2012-03-13 | University Of South Florida | Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments |
| US20100247427A1 (en) * | 2005-10-14 | 2010-09-30 | University Of South Florida | Methods of inhibiting cell growth and methods of enhancing radiation responses |
| DE102006040647A1 (de) * | 2006-08-30 | 2008-03-13 | Robert Bosch Gmbh | Handwerkzeugmaschine |
| US8895610B1 (en) | 2007-05-18 | 2014-11-25 | Heldi Kay | Platinum (IV) compounds targeting zinc finger domains |
| US8026382B2 (en) | 2007-05-18 | 2011-09-27 | Heidi Kay | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods |
| EP2170913A1 (en) * | 2007-06-18 | 2010-04-07 | Platco Technologies (Proprietary) Limited | Platinum (iv) complexes |
| HRP20160430T1 (hr) * | 2007-09-10 | 2016-05-20 | Boston Biomedical, Inc. | Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma |
| WO2010067335A1 (en) | 2008-12-12 | 2010-06-17 | Platco Technologies (Proprietary) Limited | Platinum (iv) complexes for use in the treatment of proliferative diseases such as cancer |
| DK2582847T3 (en) | 2010-06-18 | 2016-12-19 | Myriad Genetics Inc | METHODS AND MATERIALS TO ASSESS loss of heterozygosity |
| ES2588979T3 (es) | 2010-08-24 | 2016-11-08 | Dana-Farber Cancer Institute, Inc. | Procedimientos para la predicción de una respuesta contra el cáncer |
| CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| RU2491936C2 (ru) * | 2011-07-11 | 2013-09-10 | Борис Николаевич Анисимов | Способ комплексного лечения больных паразитарными заболеваниями |
| AU2012358244A1 (en) | 2011-12-21 | 2014-06-12 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| CA3080441A1 (en) | 2012-02-23 | 2013-09-06 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| WO2014160080A1 (en) | 2013-03-14 | 2014-10-02 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| EP2976347B1 (en) | 2013-03-15 | 2022-01-19 | McFarland, Sherri Ann | Metal-based coordination complexes as photodynamic compounds and their use |
| ES2777228T3 (es) | 2013-04-05 | 2020-08-04 | Myriad Genetics Inc | Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer |
| WO2014198140A1 (zh) * | 2013-06-13 | 2014-12-18 | 上海医药工业研究院 | 一种铂（ⅱ）配合物、其制备方法、药物组合物及应用 |
| US20160185808A1 (en) * | 2013-07-25 | 2016-06-30 | Srinivas Ganta | Platinum derivatives for hydrophobic formulations |
| EP4023765A1 (en) | 2013-12-09 | 2022-07-06 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| CA2958801A1 (en) | 2014-08-15 | 2016-02-18 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| CA2988989A1 (en) | 2015-06-19 | 2016-12-22 | Syn-Nat Products Enterprise LLC | Composition containing carboplatin and use |
| WO2016205785A1 (en) | 2015-06-19 | 2016-12-22 | Syn-Nat Products Enterprise LLC | Pharmaceutical composition of carboplatin based co-crystals and use thereof |
| JP6929234B2 (ja) | 2015-06-25 | 2021-09-01 | シン−ナット プロダクツ エンタープライズ エルエルシー | 医薬共結晶組成物及びその用途 |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| CN111356454B (zh) | 2017-11-21 | 2023-04-07 | 湖南湘源美东医药科技有限公司 | 含有双环铂的组合产品、其制备方法及其用途 |
| CN112175014B (zh) * | 2020-10-10 | 2021-08-20 | 中国药科大学 | 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途 |
| EP4141127B1 (en) | 2021-08-30 | 2024-10-09 | Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln | Method for assessing homologous recombination deficiency in ovarian cancer cells |
| WO2024063828A1 (en) | 2022-09-21 | 2024-03-28 | Oracle International Corporation | Expert-optimal correlation: contamination factor identification for unsupervised anomaly detection |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177263A (en) * | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| GR851932B (enExample) * | 1984-08-14 | 1985-12-13 | Engelhard Corp | |
| JPS6296A (ja) * | 1985-03-06 | 1987-01-06 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金（２）錯体 |
| JPH01156989A (ja) * | 1987-09-25 | 1989-06-20 | Ss Pharmaceut Co Ltd | 新規白金錯体 |
| ES2063119T3 (es) * | 1988-02-02 | 1995-01-01 | Johnson Matthey Inc | Complejos de pt (iv). |
| JP3520367B2 (ja) * | 1994-12-22 | 2004-04-19 | 独立行政法人産業技術総合研究所 | 白金ニトロアンミン系錯体の製造方法 |
| US6008395A (en) * | 1995-02-28 | 1999-12-28 | Kidani; Yoshinori | Platinum (IV) complex, production process thereof and carcinostatic agent containing the same |
| US5922689A (en) * | 1995-09-11 | 1999-07-13 | Unitech Pharmaceuticals, Inc. | Cisplatin analogs for cancer treatment |
| US5849790A (en) * | 1995-11-17 | 1998-12-15 | The University Of South Florida | (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents |
| US6145688A (en) * | 1996-07-17 | 2000-11-14 | Smith; James C. | Closure device for containers |
| US5977393A (en) | 1997-11-21 | 1999-11-02 | California Institute Of Technology | Schiff base derivatives of ruthenium and osmium olefin metathesis catalysts |
| KR100246722B1 (ko) * | 1997-12-30 | 2000-04-01 | 박호군 | 경구용 백금 착화합물 항암제 및 그 제조방법 |
| AU758903B2 (en) * | 1998-11-26 | 2003-04-03 | Pentapharm Ag | Transport system conjugate |
| JP2003525862A (ja) * | 1999-01-27 | 2003-09-02 | ザ ユニヴァーシティー オブ サウス フロリダ | ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害 |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
| EP1345956A2 (en) | 2000-10-13 | 2003-09-24 | University of Lausanne | Intracellular delivery of biological effectors by novel transporter peptide sequences |
| US7638122B2 (en) * | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
| WO2005002508A2 (en) * | 2003-06-11 | 2005-01-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| WO2005023824A2 (en) * | 2003-08-13 | 2005-03-17 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| US20050288365A1 (en) | 2004-01-06 | 2005-12-29 | Heidi Kay | Platinum complexes and methods for inhibiting tumor cell proliferation |
| CA2587779A1 (en) | 2004-11-10 | 2007-01-18 | University Of South Florida | Platinum complexes for targeted drug delivery |
| WO2007006019A1 (en) | 2005-07-06 | 2007-01-11 | University Of South Florida | Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression |
-
2004
- 2004-08-13 WO PCT/US2004/026392 patent/WO2005023824A2/en not_active Ceased
- 2004-08-13 AT AT04781131T patent/ATE453653T1/de not_active IP Right Cessation
- 2004-08-13 JP JP2006523414A patent/JP2007502777A/ja active Pending
- 2004-08-13 AU AU2004264421A patent/AU2004264421B2/en not_active Ceased
- 2004-08-13 CA CA002535584A patent/CA2535584A1/en not_active Abandoned
- 2004-08-13 AU AU2004270655A patent/AU2004270655B2/en not_active Ceased
- 2004-08-13 US US10/918,762 patent/US7238372B2/en not_active Expired - Lifetime
- 2004-08-13 EP EP04809566A patent/EP1664070B1/en not_active Expired - Lifetime
- 2004-08-13 AT AT04809566T patent/ATE404574T1/de not_active IP Right Cessation
- 2004-08-13 CA CA002535762A patent/CA2535762A1/en not_active Abandoned
- 2004-08-13 DE DE602004015811T patent/DE602004015811D1/de not_active Expired - Lifetime
- 2004-08-13 WO PCT/US2004/026393 patent/WO2005016946A2/en not_active Ceased
- 2004-08-13 JP JP2006523413A patent/JP2007502301A/ja active Pending
- 2004-08-13 US US10/918,769 patent/US7566798B2/en not_active Expired - Fee Related
- 2004-08-13 DE DE602004024909T patent/DE602004024909D1/de not_active Expired - Lifetime
- 2004-08-13 EP EP04781131A patent/EP1675864B1/en not_active Expired - Lifetime
-
2007
- 2007-01-31 US US11/701,907 patent/US7763585B2/en not_active Expired - Fee Related
-
2009
- 2009-07-21 US US12/506,913 patent/US7759510B2/en not_active Expired - Fee Related
-
2010
- 2010-07-13 US US12/835,114 patent/US8247445B2/en not_active Expired - Fee Related
- 2010-07-15 US US12/837,046 patent/US8598230B2/en not_active Expired - Fee Related
-
2011
- 2011-05-23 AU AU2011202386A patent/AU2011202386A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502777A5 (enExample) | ||
| EP1675864B1 (en) | Platinum complexes for the treatment of tumors | |
| JP2009531403A5 (enExample) | ||
| JP2001517699A5 (enExample) | ||
| CN105189607B (zh) | 胺官能性聚酰胺 | |
| JP2019511483A5 (enExample) | ||
| US7977381B2 (en) | Platinum complexes and methods for inhibiting tumor cell proliferation | |
| JPWO2019195124A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| JP2009511423A5 (enExample) | ||
| JP2010500293A5 (enExample) | ||
| RU2005137032A (ru) | Применение оксазолидинон-хинолиновых гибридных антибиотиков для лечения сибирской язвы и других инфекций | |
| JP2005511699A5 (enExample) | ||
| JP2004502755A5 (enExample) | ||
| KR20180053337A (ko) | 제약 화합물 | |
| US10508126B2 (en) | Bisphosphonates vinylic monomers and polymers and uses thereof | |
| JP2006525368A5 (enExample) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral | |
| JP2009515984A5 (enExample) | ||
| JP2003505513A5 (enExample) | ||
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| EP0864578A2 (en) | Platinum (IV) complex and pharmaceutical composition comprising the same | |
| JP2019518029A5 (enExample) | ||
| RU2440113C2 (ru) | Фармацевтическая композиция для инъекционного особенно целенаправленного местного применения |